Q-omics provides the consensus-scored HCN2 profile across patient tissues and cancer cell-line models. HCN2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, HCN2 is differentially expressed in 15, with the highest sampling consensus in KICH. Additionally, HCN2 RNA expression shows 17,187 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, KICH, and TGCT as cancer lineages where HCN2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HCN2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HCN2 survival associations across molecular data types. HCN2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HCN2 RNA expression–survival associations across cancer types. High HCN2 expression shows unfavorable associations in KIRC, UVM, BLCA, ACC, KIRP and COAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for HCN2 RNA expression.
This table summarizes HCN2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for HCN2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HCN2 shows lower tumor expression in KIRC and higher tumor expression in KICH, LUAD, LIHC, BLCA and BRCA. The KICH box plot shows higher HCN2 RNA expression in tumor versus normal tissue (log2 FC = +5.083, t-test p < 0.001).
This table shows molecular features associated with HCN2 in patient tissues and cancer cell lines. In patient samples, HCN2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, HCN2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and CNS.
